HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Seaport Therapeutics (NASDAQ: SPTX) and maintained a price target of $50 for the stock.